This groundbreaking finding, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, suggests that ...

In July 2024, people living with early Alzheimer’s and organizations such as the Alzheimer’s Association celebrated FDA ...

Learn about early-onset Alzheimer's through real stories of hope and breakthrough treatments that are changing lives of patients diagnosed before age ...

Since its approval in 2023, the Alzheimer's disease drug made by Biogen Inc. and Eisai has seen a lackluster launch. However, ...

Discover the impact of alcohol-related dementia, its symptoms, risk factors, and treatment options. Learn how alcohol misuse ...

Research reveals how herpes simplex virus-1 may contribute to Alzheimer’s disease, offering new insights into the disease’s ...

Recent studies implicate the immune system and a herpes virus as potential contributors to development of disease ...

The Phase Ia trial is designed to assess the safety and efficacy of the company’s drug designed to target chemicals thought ...

New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according ...

The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...

A predictive tool for determining the age at which individuals may develop mild cognitive impairment (MCI) or Alzheimer's ...